Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

Wagner, Anna D.; Grothe, Wilfried; Haerting, Johannes; Kleber, Gerhard; Grothey, Axel; Fleig, Wolfgang E.

doi:10.1200/jco.2005.05.0245

Cited by 1,171Gastric Cancer Management and OutcomesColorectal Cancer Treatments and StudiesIntraperitoneal and Appendiceal Malignancies

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

Open access

Wagner, Anna D., Grothe, Wilfried, Haerting, Johannes, Kleber, Gerhard, Grothey, Axel, Fleig, Wolfgang E.·2006·Journal of Clinical Oncology

DOI 10.1200/jco.2005.05.0245

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: This systematic review and meta-analysis were performed to assess the efficacy and tolerability of chemotherapy in patients with advanced gastric cancer. Methods: Randomized phase II and III clinical trials on first-line chemotherapy in advanced gastric cancer were identified by electronic searches of Medline, Embase, the Cochrane Controlled Trials Register, and Cancerlit; hand searches of relevant abstract books and reference lists; and contact to experts. Meta-analysis was performed using the fixed-effect model. Overall survival, reported as hazard ratio (HR) with 95% CI, was the primary outcome measure. Results: Analysis of chemotherapy versus best supportive care (HR = 0.39; 95% CI, 0.28 to 0.52) and combination versus single agent, mainly fluorouracil (FU) -based chemotherapy (HR = 0.83; 95% CI = 0.74 to 0.93) showed significant overall survival benefits in favor of chemotherapy and combination chemotherapy, respectively. In addition, comparisons of FU/cisplatin-containing regimens with versus without anthracyclines (HR = 0.77; 95% CI, 0.62 to 0.95) and FU/anthracycline-containing combinations with versus without cisplatin (HR = 0.83; 95% CI, 0.76 to 0.91) both demonstrated a significant survival benefit for the three-drug combination. Comparing irinotecan-containing versus nonirinotecan-containing combinations (mainly FU/cisplatin) resulted in a nonsignificant survival benefit in favor of the irinotecan-containing regimens (HR = 0.88; 95% CI, 0.73 to 1.06), but they have never been compared against a three-drug combination. Conclusion: Best survival results are achieved with three-drug regimens containing FU, an anthracycline, and cisplatin. Among these, regimens including FU as bolus exhibit a higher rate of toxic deaths than regimens using a continuous infusion of FU, such as epirubicin, cisplatin, and continuous-infusion FU.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2005.05.0245

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5-FU inhibits thymidylate synthase, limiting thymidine nucleotides for DNA synthesis, and 5-FU and capecitabine remain widely used and important for gastrointestinal cancers.
“The pyrimidine analogue 5-fluorouracil (5-FU) is a synthetic analogue of uracil that inhibits thymidylate synthase, limiting the availability of thymidine nucleotides for DNA synthesis (Figure 1b, Figure 2c). 5-FU and the related 5-FU-prodrug capecitabine remain widely used chemotherapies today and are an important treatment for gastrointestinal cancers (Heidelberger et al., 1957; Wagner et al., 2”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Wagner et al., 2006

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Practical Statistics for Medical Research.
Walter, S., & Altman, D. G. (1992) · Biometrics · doi:10.2307/2532320 · Cited by 11,665 · see citing works
Practical Statistics for Medical Research
Altman, D. G. (1990) · doi:10.1201/9780429258589 · Cited by 10,668 · see citing works
Chemotherapy for advanced gastric cancer
Wagner, D., Syn, N. L. X., Moehler, M. H., Grothe, W., Yong, W. P., Tai, B., Ho, J., & Unverzagt, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub4 · Cited by 1,385 · see citing works
Self-citation
Palliative Care
Sepulveda, C. R., Marlin, A., Yoshida, T., & Ullrich, A. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00440-2 · Cited by 1,295 · see citing works
A Survey of Exact Inference for Contingency Tables
Agresti, A. (1992) · Statistical Science · doi:10.1214/ss/1177011454 · Cited by 1,110 · see citing works
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
Grothey, A., Sargent, D., Goldberg, R. M., & Schmoll, H.-J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.037 · Cited by 1,070 · see citing works
Self-citation
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
Webb, A., Cunningham, D., Scarffe, J. H., Harper, P., Norman, A. R., Joffe, J., Hughes, M., Mansi, J., Findlay, M., Hill, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.261 · Cited by 868 · see citing works
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer
Glimelius, B. L. G., Ekström, K., Hoffman, K., Graf, W. D., Sjödén, P., Haglund, U., Svensson, C., Enander, L. K., Linné, T., Sellsröm, H., et al. (1997) · Annals of Oncology · doi:10.1023/a:1008243606668 · Cited by 844 · see citing works
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer
Pyrhönen, S. O., Kuitunen, T., Nyandoto, P., & Kouri, M. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.114 · Cited by 786 · see citing works
Gastric cancer epidemiology and risk factors
Kelley, J. R., & Duggan, J. M. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(02)00534-6 · Cited by 752 · see citing works
Systematic reviews of evaluations of prognostic variables
Altman, D. G. (2001) · BMJ · doi:10.1136/bmj.323.7306.224 · Cited by 751 · see citing works
Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer
Ross, P. J., Nicolson, M. C., Cunningham, D., Valle, J. W., Seymour, M., Harper, P., Price, T. J., Anderson, H., Iveson, T. J., Hickish, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.105 · Cited by 474 · see citing works
Randomized Phase III Trial of Fluorouracil Alone Versus Fluorouracil Plus Cisplatin Versus Uracil and Tegafur Plus Mitomycin in Patients With Unresectable, Advanced Gastric Cancer: The Japan Clinical Oncology Group Study (JCOG9205)
Ohtsu, A., Shimada, Y., Shirao, K., Boku, N., Hyodo, I., Saito, H., Yamamichi, N., Miyata, Y., Ikeda, N., Yamamoto, S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.130 · Cited by 425 · see citing works
A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin
Cullinan, S. A. (1985) · JAMA · doi:10.1001/jama.253.14.2061 · Cited by 394 · see citing works
Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: A follow-up study based on 138 cases from a diagnostic variability study
Montgomery, E., Goldblum, J. R., Greenson, J. K., Haber, M. M., Lamps, L. W., Lauwers, G. Y., Lazenby, A. J., Lewin, D., Robert, M. E., Washington, K. M., et al. (2001) · Human Pathology · doi:10.1053/hupa.2001.23511 · Cited by 290 · see citing works
Randomized Multicenter Phase II Trial of a Biweekly Regimen of Fluorouracil and Leucovorin (LV5FU2), LV5FU2 Plus Cisplatin, or LV5FU2 Plus Irinotecan in Patients With Previously Untreated Metastatic Gastric Cancer: A Fédération Francophone de Cancérologie Digestive Group Study—FFCD 9803
Bouché, O., Raoul, J., Bonnetain, F., Giovannini, M. F., Etienne, P. L., Lledo, G., Arsène, D., Paitel, J. F., Guerin‐Meyer, V., Mitry, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.140 · Cited by 271 · see citing works
The rising trend in oesophageal adenocarcinoma and gastric cardia
Powell, J., & McConkey, C. (1992) · European Journal of Cancer Prevention · doi:10.1097/00008469-199204000-00008 · Cited by 250 · see citing works
Palliative chemotherapy for advanced gastric cancer
Wöhrer, S., Raderer, M., & Hejna, M. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh422 · Cited by 175 · see citing works
Phase I/II Study of Cetuximab in Combination With Cisplatin or Carboplatin and Fluorouracil in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Bourhis, J., Rivera, F., Mesı́a, R., Awada, A. H., Geoffrois, L., Borel, C., Humblet, Y., Pousa, A. L., Hitt, R., Villegas, M. E. V., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3547 · Cited by 174 · see citing works
Helicobacter pylori and gastric cancer: state of the art.
Corréa, P. (1996) · PubMed · Cited by 159 · see citing works
Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study
Pozzo, C., Barone, C., Szántó, J., Pádi, É., Peschel, C., Bükki, J., Горбунова, В. А., Valvere, V., Załuski, J., Biakhov, M. Y., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh473 · Cited by 157 · see citing works
Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF
Sumpter, K., Harper-Wynne, C. L., Cunningham, D., Rao, S., Tebbutt, N. C., Norman, A. R., Ward, C., Iveson, T. J., Nicolson, M. C., Hickish, T., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602572 · Cited by 147 · see citing works
Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group.
Cullinan, S. A., Moertel, C. G., Wieand, H. S., O'Connell, M. J., Poon, M. A., Krook, J. E., Mailliard, J. A., & Tschetter, L. K. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.2.412 · Cited by 134 · see citing works
Systematic Reviews of Evaluations of Prognostic Variables
Altman, D. G. (2001) · Wiley eBooks · doi:10.1002/9780470693926.ch13 · Cited by 123 · see citing works
Rising incidence of oesophageal adenocarcinoma in men in Australia
Lord, R. V., Law, M. G., Ward, R. L., Giles, G. G., Thomas, R. J. S., & Thursfield, V. J. (1998) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.1998.tb00646.x · Cited by 108 · see citing works
Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research.
Cocconi, G., Bella, M. A., Zironi, S., Algeri, R., Costanzo, F. D., Lisi, V. D., Luppi, G., Mazzocchi, B., Rodinò, C., & Soldani, M. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.12.2687 · Cited by 105 · see citing works
Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer
Moehler, M. H., Eimermacher, A., Siebler, J., Höhler, T., Wein, A., Menges, M., Flieger, D., Junginger, T., Geer, T., Gracien, E., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602649 · Cited by 97 · see citing works
Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st-line advanced gastric cancer patients
Dank, M., Załuski, J., Barone, C., Valvere, V., Peschel, C., Wenczl, M., Göker, E., Risse, M., Awad, L., & Bugat, R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.4003 · Cited by 87 · see citing works
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial
Köhne, C.-H., Catane, R., Klein, B., Ducreux, M. P., Thuss-Patience, P. C., Niederle, N., Gips, M., Preusser, P., Knuth, A., Clemens, M., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601226 · Cited by 86 · see citing works
Mortality associated with daily bolus 5‐fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin
Delaunoit, T., Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Findlay, B., Thomas, S. P., Salim, M., Schaefer, P., Stella, P. J., et al. (2004) · Cancer · doi:10.1002/cncr.20594 · Cited by 76 · see citing works
Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC)
Moiseyenko, V. M., Ajani, J. A., Tjulandin, S. A., Majlis, A., Constenla, M., Boni, C., Anelli, A., Yver, A., & Cutsem, E. V. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.4002 · Cited by 73 · see citing works
Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies.
Levi, J. A., Fox, R. M., Tattersall, M. H. N., Woods, R. L., Thomson, D. B., & Gill, G. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.9.1348 · Cited by 72 · see citing works
One-year survey of carcinoma of the oesophagus and stomach in Wales
Pye, J. K., Crumplin, M. K. H., Charles, J., Kerwat, R., Foster, M. E., & Biffin, A. (2001) · British journal of surgery · doi:10.1046/j.1365-2168.2001.01655.x · Cited by 69 · see citing works
Chemotherapy for advanced gastric cancer
Wagner, D., Grothe, W. W., Behl, S., Kleber, G., Grothey, A. A., Haerting, J., & Fleig, W. E. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub2 · Cited by 68 · see citing works
Self-citation
Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma
Cocconi, G., Carlini, P., Gamboni, A., Gasperoni, S., Rodinò, C., Zironi, S., Bisagni, G., Porrozzi, S., Cognetti, F., Costanzo, F. D., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg329 · Cited by 64 · see citing works
Non–Islet-Cell Tumor Induced Hypoglycemia in Patients With Advanced Gastrointestinal Stromal Tumor Possibly Worsened By Imatinib
Hamberg, P., de Jong, F. A., Boonstra, J. G., van Doorn, J., Verweij, J., & Sleijfer, S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5318 · Cited by 56 · see citing works
Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK)
Roth, A., Maibach, R., Falk, S., Stupp, R., Saletti, P., Kãberle, D., Borner, M., Honegger, H., Leslie, M., & Fazio, N. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.4020 · Cited by 56 · see citing works
An increased relative frequency of retinoblastoma at a rural regional referral hospital in Miraj, Maharashtra, India
Schultz, K. R., Ranade, S., Neglia, J. P., & Ravindranath, Y. (1993) · Cancer · doi:10.1002/1097-0142(19930701)72:1 · Cited by 50 · see citing works
The Role of Prevention in Oncology Practice: Results From a 2004 Survey of American Society of Clinical Oncology Members
Ganz, P. A., Kwan, L. C., Somerfield, M. R., Alberts, D. S., Garber, J. E., Offit, K., & Lippman, S. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.8321 · Cited by 48 · see citing works
Randomized comparison of 5-FU alone or combined with carmustine, doxorubicin, and mitomycin (BAFMi) in the treatment of advanced gastric cancer: a phase III trial of the Italian Clinical Research Oncology Group (GOIRC).
Lisi, V. D., Cocconi, G., Tonato, M., Costanzo, F. D., Leonardi, F., & Soldani, M. (1986) · PubMed · Cited by 43 · see citing works
Triazinate and Platinum Efficacy in Combination With 5-Fluorouracil and Doxorubicin: Results of a Three-Arm Randomized Trial in Metastatic Gastric Cancer
Gastrointestinal Tumor Study Group (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.13.1011 · Cited by 28 · see citing works
Mitosis identification in diffuse gliomas
Coons, S. W., & Pearl, D. K. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980415)82:8 · Cited by 27 · see citing works
High Doses of 5-Fluorouracil and Epirubicin with or without Cisplatin in Advanced Gastric Cancer: A Randomized Study
Roth, A., Kolarić, K., Županc, D., Orešić, V., Roth, A., & Ebling, Z. (1999) · Tumori Journal · doi:10.1177/030089169908500404 · Cited by 27 · see citing works
A prospective randomized phase III trial of 5-fluorouracil and cisplatin (FP) versus epirubicin, cisplatin, and 5-fu (ECF) in the treatment of patients with previously untreated advanced gastric cancer (AGC)
Kim, T. W., Choi, S.-L., Ahn, J., Bang, H. S., Chang, H. M., Kang, Y. K., Lee, J. S., Kim, W. K., & Kim, S. H. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)81651-8 · Cited by 23 · see citing works
5-Fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma
Loehrer, P. J., Harry, D., & Chlebowski, R. T. (1994) · Investigational New Drugs · doi:10.1007/bf00873238 · Cited by 22 · see citing works
Docetaxel-cisplatin (DC) versus 5-fluorouracil-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase III study
Ridwelski, K., Fahlke, J., Kettner, E., Schmidt, C., Keilholz, U., Quietzsch, D., Aßmann, M., Stauch, M. B., Zierau, K., & Lippert, H. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.4512 · Cited by 20 · see citing works
Efficacy of the Association of Folinic Acid and 5-Fluorouracil Alone Versus Folinic Acid and 5-Fluorouracil Plus 4-Epidoxorubicin in the Treatment of Advanced Gastric Carcinoma
Colucci, G., Giotta, F., Maiello, E., Cifarelli, R. A., Leo, S., Giuliani, F., Pezzella, G., Pedicini, A., & Valori, V. M. (1995) · American Journal of Clinical Oncology · doi:10.1097/00000421-199512000-00012 · Cited by 18 · see citing works
[Randomized controlled study on chemotherapy with 5-FD, ADM plus CDDP in advanced gastric carcinoma].
Kikuchi, K., Wakui, A., Shimizu, H., & Kunii, Y. (1990) · PubMed · Cited by 9 · see citing works
[A randomized controlled trial with methotrexate (MTX), 5-fluorouracil (5-FU) and pirarubicin (THP) vs 5-FU alone in advanced or recurrent gastric carcinoma. Tokai Hokuriku THP Study Group].
Yamamura, Y., Miyazaki, I., Ogawa, M., Yonemura, Y., TANEMURA, H., Kito, T., Hamajima, N., Saji, S., & Kosaka, T. (1998) · PubMed · Cited by 8 · see citing works
562 High doses of epirubicin and 5-fluorouracil with or without cisplatin in advanced gastric cancer
Roth, A. D., Kolarić, K., & Županc, D. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)95816-o · Cited by 2 · see citing works
Docetaxel-cisplatin (DC) versus 5-fluorouracil-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary safety results of a phase III study
Fahlke, J., Ridwelski, K., Schmidt, C., Kettner, E., Quitzsch, D., Keilholz, U., Assmann, M., Florschütz, A., Stauch, M., & Lippert, H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.4045 · Cited by 2 · see citing works

Flagged first, then by citations

Sorted by citations

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302 · see citing works
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Wilke, H., Muro, K., Cutsem, E. V., Oh, S., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T.-Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70420-6 · Cited by 2,200 · see citing works
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Cunningham, D., Starling, N., Rao, S., Iveson, T. J., Nicolson, M. C., Coxon, F. Y., Middleton, G., Daniel, F., Oates, J. R., & Norman, A. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa073149 · Cited by 2,282 · see citing works
Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial
Songun, I., Putter, H., Kranenbarg, E. M., Sasako, M., & van de Velde, C. J. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70070-x · Cited by 1,767 · see citing works
Chemotherapy for advanced gastric cancer
Wagner, D., Syn, N. L. X., Moehler, M. H., Grothe, W., Yong, W. P., Tai, B., Ho, J., & Unverzagt, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub4 · Cited by 1,385 · see citing works
Self-citation
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
Grávalos, C., & Jimeno, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn169 · Cited by 1,183 · see citing works
Targeting Metabolism for Cancer Therapy
Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971 · see citing works
Gastric cancer
Hartgrink, H. H., Jansen, E. P. M., van Grieken, N. C. T., & van de Velde, C. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60617-6 · Cited by 900 · see citing works
The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer
Wang, F., Shen, L., Li, J., Zhou, Z., Liang, H., Zhang, X., Tang, L., Xin, Y., Jin, J., Zhang, Y., et al. (2019) · 癌症：英文版 · doi:10.1186/s40880-019-0349-9 · Cited by 814 · see citing works
Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
Kang, J. H., Lee, S. I., Lim, D. H., Park, K. W., Oh, S. Y., Kwon, H., Hwang, I. G., Lee, S., Nam, E., Shin, D. B., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.4585 · Cited by 658 · see citing works
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
Wang, F., Zhang, X., Li, Y., Tang, L., Qu, X., Ying, J., Zhang, J., Sun, L., Lin, R., Qiu, H., et al. (2021) · 癌症：英文版 · doi:10.1002/cac2.12193 · Cited by 614 · see citing works
Treatment of gastric cancer
Orditura, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i7.1635 · Cited by 624 · see citing works
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
Boku, N., Yamamoto, S., Fukuda, H., Shirao, K., Doi, T., Sawaki, A., Koizumi, W., Saito, H., Yamaguchi, K., Takiuchi, H., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70259-1 · Cited by 587 · see citing works
Advanced gastric cancer: Current treatment landscape and future perspectives
Digklia, A. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i8.2403 · Cited by 560 · see citing works
Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up
Glynne‐Jones, R., Nilsson, P. J., Aschele, C., Goh, V., Peiffert, D., Cervantes, A. M. R., & Arnold, D. (2014) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2014.07.030 · Cited by 482 · see citing works
Chemotherapy for advanced gastric cancer
Wagner, D., Unverzagt, S., Grothe, W., Kleber, G., Grothey, A., Haerting, J., & Fleig, W. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub3 · Cited by 470 · see citing works
Self-citation
Management of gastric cancer in Asia: resource-stratified guidelines
Shen, L., Shan, Y., Hu, H., Price, T. J., Sirohi, B., Yeh, K., Yang, Y., Sano, T., Yang, H., Zhang, X., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70436-4 · Cited by 461 · see citing works
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
Wang, F., Zhang, X., Tang, L., Wu, Q., Cai, M., Li, Y., Qu, X., Qiu, H., Zhang, Y., Ying, J., et al. (2023) · 癌症：英文版 · doi:10.1002/cac2.12516 · Cited by 437 · see citing works
Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach
Guideline Committee of the Korean Gastric Cancer Association (KGCA), D. W. G. &. R. P. (2019) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2019.19.e8 · Cited by 393 · see citing works
Gastric cancer
Catalano, V., Labianca, R., Beretta, G. D., Gatta, G., de Braud, F., & Cutsem, E. V. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.01.004 · Cited by 380 · see citing works
Apparent Diffusion Coefficient: Potential Imaging Biomarker for Prediction and Early Detection of Response to Chemotherapy in Hepatic Metastases
Cui, Y., Zhang, X., Sun, Y., Tang, L., & Shen, L. (2008) · Radiology · doi:10.1148/radiol.2483071407 · Cited by 360 · see citing works
Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy
Tan, I. B., Ivanova, T., Lim, K. H., Ong, C. W., Deng, N., Lee, J., Tan, S. H., Wu, J., Lee, M. H., Ooi, C.-H., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.04.042 · Cited by 357 · see citing works
Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Glynne‐Jones, R., Nilsson, P. J., Aschele, C., Goh, V., Peiffert, D., Cervantes, A. M. R., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu159 · Cited by 354 · see citing works
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
Dank, M., Załuski, J., Barone, C. A., Valvere, V., Yalçın, S. S., Peschel, C., Wenczl, M., Göker, E., Cisar, L. A., Wang, K., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn166 · Cited by 344 · see citing works
Signaling pathways and therapeutic interventions in gastric cancer
Lei, Z., Teng, Q., Qin, T. L., Chen, W., Xie, Y., Wu, K., Zeng, Q., Zeng, L., Pan, Y., Chen, Z., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01190-w · Cited by 325 · see citing works
Oesophageal cancer
Yang, H., Wang, F., Hallemeier, C. L., Lerut, T., & Fu, J. (2024) · The Lancet · doi:10.1016/s0140-6736(24)02226-8 · Cited by 313 · see citing works
Gastric cancer: ESMO–ESSO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Waddell, T. K., Verheij, M., Allum, W., Cunningham, D., Cervantes, A. M. R., & Arnold, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt344 · Cited by 303 · see citing works
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction
Valle, J. W., Armstrong, A., Newman, C., Alakhov, V., Pietrzynski, G., Brewer, J., Campbell, S., Corrie, P., Rowinsky, E. K., & Ranson, M. (2011) · Investigational New Drugs · doi:10.1007/s10637-010-9399-1 · Cited by 303 · see citing works
S3-Leitlinie „Magenkarzinom” –
Moehler, M., Al-Batran, S., Andus, T., Anthuber, M., Arends, J., Arnold, D., Aust, D., Baier, P., Baretton, G., Bernhardt, J., et al. (2011) · Zeitschrift für Gastroenterologie - German Journal of Gastroenterology · doi:10.1055/s-0031-1273201 · Cited by 231 · see citing works
Self-citation
Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy
Lee, S., Oh, S. Y., Kim, S. H., Lee, J. H., Kim, M. C., Kim, K. H., & Kim, H. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-350 · Cited by 282 · see citing works
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
Pinto, C., Fabio, F. D., Siena, S., Cascinu, S., Llimpe, F. L. R., Ceccarelli, C., Mutri, V., Giannetta, L. G., Giaquinta, S., Funaioli, C., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl459 · Cited by 281 · see citing works
Cancer Cells Tune the Signaling Pathways to Empower de Novo Synthesis of Nucleotides
Villa, E., Ali, E. S., Sahu, U., & Ben‐Sahra, I. (2019) · Cancers · doi:10.3390/cancers11050688 · Cited by 276 · see citing works
Anal cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up
Glynne‐Jones, R., Nilsson, P. J., Aschele, C., Goh, V., Peiffert, D., Cervantes, A. M. R., & Arnold, D. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2014.04.013 · Cited by 269 · see citing works
Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) Study
Guimbaud, R., Louvet, C., Ries, P., Ychou, M., Maillard, E., André, T., Gornet, J., Aparicio, T., Nguyen, S., Azzedine, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.1011 · Cited by 262 · see citing works
Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer
Okines, A. F. C., Norman, A. R., McCloud, P., Kang, Y., & Cunningham, D. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp047 · Cited by 258 · see citing works
Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments
McQuade, R. M., Stojanovska, V., Abalo, R., Bornstein, J. C., & Nurgali, K. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00414 · Cited by 251 · see citing works
Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer
Liu, H., Zhu, L., Liu, B., Liu, Y., Meng, X., Zhang, W., Ma, Y., & Xiao, H. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.10.034 · Cited by 250 · see citing works
Associations among prognostic understanding, quality of life, and mood in patients with advanced cancer
El‐Jawahri, A., Traeger, L., Park, E. R., Greer, J. A., Pirl, W. F., Lennes, I. T., Jackson, V. A., Gallagher, E. R., & Temel, J. S. (2014) · Cancer · doi:10.1002/cncr.28369 · Cited by 240 · see citing works
The neutrophil-to-lymphocyte ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients
Miyamoto, R., Inagawa, S., Sano, N., Tadano, S., Adachi, S., & Yamamoto, M. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.02.003 · Cited by 240 · see citing works
Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) is an Independent Prognostic Indicator of Worse Outcome in Gastric Cancer Patients
Lieto, E., Ferraraccio, F., Orditura, M., Castellano, P., Mura, A. L., Pinto, M., Zamboli, A. G. I., Vita, F. D., & Galizia, G. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9596-0 · Cited by 237 · see citing works
Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008
Morton, L. M., Dores, G. M., Tucker, M. A., Kim, C. J., Onel, K., Gilbert, E. S., Fraumeni, J. F., & Curtis, R. E. (2013) · Blood · doi:10.1182/blood-2012-08-448068 · Cited by 233 · see citing works
International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of Chemotherapy in Older Patients—An Analysis of the Medical Literature
Lichtman, S. M., Wildiers, H. P. M. W., Chatelut, É., Steer, C., Budman, D. R., Morrison, V. A., Tranchand, B., Shapira, I., & Aapro, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.6583 · Cited by 221 · see citing works
Update on Metastatic Gastric and Esophageal Cancers
Shah, M. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.1799 · Cited by 213 · see citing works
Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer
Zeng, Y., & Jin, R. U. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.12.004 · Cited by 214 · see citing works
Toward understanding the selective anticancer capacity of cold atmospheric plasma—A model based on aquaporins (Review)
Yan, D., Talbot, A., Nourmohammadi, N., Sherman, J. H., Cheng, X., & Keidar, M. (2015) · Biointerphases · doi:10.1116/1.4938020 · Cited by 208 · see citing works
Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer
Hall, P. S., Swinson, D., Cairns, D. A., Waters, J. S., Petty, R., Allmark, C., Ruddock, S., Falk, S. J., Wadsley, J., Roy, R., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.0848 · Cited by 198 · see citing works
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
Bang, Y., Kang, Y., Kang, W. K., Boku, N., Chung, H. C., Chen, J., Doi, T., Sun, Y. P., Shen, L., Qin, S., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9438-y · Cited by 192 · see citing works
The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015
Manzoni, G. D., Marrelli, D., Baiocchi, G. L., Morgagni, P., Saragoni, L., Degiuli, M., Donini, A., Fumagalli, U., Mazzei, M. A., Pacelli, F., et al. (2016) · Gastric Cancer · doi:10.1007/s10120-016-0615-3 · Cited by 190 · see citing works
Gastric Cancer: A Primer on the Epidemiology and Biology of the Disease and an Overview of the Medical Management of Advanced Disease
Shah, M. A., & Kelsen, D. P. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0033 · Cited by 189 · see citing works
Level of HER2 Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab
Gómez-Martín, C., Plaza, C., Pazo-Cid, R., Salud, A., Pons, F., Fonseca, P., León, A., Alsina, M., Visa, L., Rivera, F., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.9070 · Cited by 189 · see citing works
RETRACTED: CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance
Yoon, C., Park, D. J., Schmidt, B. H., Thomas, N. J., Lee, H., Kim, T. S., Janjigian, Y. Y., Cohen, D. J., & Yoon, S. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0011 · Cited by 186 · see citing works
Retracted
Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil With Bevacizumab in Patients With Metastatic Gastroesophageal Adenocarcinoma
Shah, M. A., Jhawer, M. P., Ilson, D. H., Lefkowitz, R. A., Robinson, E. A. E., Capanu, M., & Kelsen, D. P. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.0770 · Cited by 186 · see citing works
Medical management of gastric cancer: a 2017 update
Charalampakis, N., Economopoulou, P., Kotsantis, I., Tolia, M., Schizas, D., Liakakos, T., Elimova, E. C., Ajani, J. A., & Psyrri, A. K. (2017) · Cancer Medicine · doi:10.1002/cam4.1274 · Cited by 178 · see citing works
Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
Lordick, F., Luber, B., Lorenzen, S., Hegewisch-Becker, S., Folprecht, G., Wöll, E., Decker, T. W., Endlicher, E., Röthling, N., Schuster, T., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605521 · Cited by 175 · see citing works
Clinical Practice Guidelines for Gastric Cancer in Korea: An Evidence-Based Approach
Lee, J. H., Kim, J. G., Jung, H., Kim, J. H., Jeong, W. K., Jeon, T. J., Kim, J. M., Kim, Y., Ryu, K. W., Kong, S., et al. (2014) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2014.14.2.87 · Cited by 175 · see citing works
Gastric cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up
Waddell, T. K., Verheij, M., Allum, W., Cunningham, D., Cervantes, A. M. R., & Arnold, D. (2014) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2013.09.020 · Cited by 167 · see citing works
The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: A randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)
Al‐Batran, S., Pauligk, C., Homann, N., Hartmann, J. T., Moehler, M. H., Probst, S., Rethwisch, V., Stoehlmacher-Williams, J., Prasnikar, N., Hollerbach, S. H., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.09.025 · Cited by 165 · see citing works
Molecular mechanisms of chemoresistance in gastric cancer
Shi, W., & Gao, J. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i9.673 · Cited by 165 · see citing works
Current questions for the treatment of advanced gastric cancer
Cervantes, A. M. R., Roda, D., Tarazona, N., Roselló, S., & Fidalgo, J. A. P. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.09.007 · Cited by 162 · see citing works
Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis
a (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.016 · Cited by 161 · see citing works
Isorhamnetin augments the anti-tumor effect of capeciatbine through the negative regulation of NF-κB signaling cascade in gastric cancer
Manu, K. A., Shanmugam, M. K., Ramachandran, L., Li, F., Siveen, K. S., Chinnathambi, A., Zayed, M. E., Alharbi, S. A., Arfuso, F., Kumar, A. P., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.03.033 · Cited by 159 · see citing works
Advanced gastric cancer – Slow but steady progress
Power, D. G., Kelsen, D. P., & Shah, M. A. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.01.005 · Cited by 156 · see citing works
Lauren Histologic Type Is the Most Important Factor Associated With Pattern of Recurrence Following Resection of Gastric Adenocarcinoma
Lee, J. H., Chang, K. K., Yoon, C., Tang, L. H., Strong, V. E. M., & Yoon, S. S. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000002040 · Cited by 156 · see citing works
Hyperglycemia Associated Metabolic and Molecular Alterations in Cancer Risk, Progression, Treatment, and Mortality
Ramteke, P. L., Deb, A., Shepal, V., & Bhat, M. K. (2019) · Cancers · doi:10.3390/cancers11091402 · Cited by 156 · see citing works
Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies
Hasegawa, S., & Yoshikawa, T. (2010) · Gastric Cancer · doi:10.1007/s10120-010-0555-2 · Cited by 150 · see citing works
Epidermal Growth Factor Receptor (EGFR) Expression is Associated With a Worse Prognosis in Gastric Cancer Patients Undergoing Curative Surgery
Galizia, G., Lieto, E., Orditura, M., Castellano, P., Mura, A. L., Imperatore, V., Pinto, M., Zamboli, A. G. I., Vita, F. D., & Ferraraccio, F. (2007) · World Journal of Surgery · doi:10.1007/s00268-007-9016-4 · Cited by 149 · see citing works
ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis
Yin, M., Yan, J., Martinez‐Balibrea, E., Graziano, F., Lenz, H., Kim, H.-J., Robert, J., Im, S., Wang, W.-S., Étienne-Grimaldi, M.-C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2169 · Cited by 147 · see citing works
First Evidence That γ-Tocotrienol Inhibits the Growth of Human Gastric Cancer and Chemosensitizes It to Capecitabine in a Xenograft Mouse Model through the Modulation of NF-κB Pathway
Manu, K. A., Shanmugam, M. K., Ramachandran, L., Li, F., Fong, C. W., Kumar, A. P., Tan, P. B. O., & Sethi, G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2470 · Cited by 146 · see citing works
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)
Pinto, C., Fabio, F. D., Barone, C. A., Siena, S., Falcone, A., Cascinu, S., Llimpe, F. L. R., Stella, G. M., Schinzari, G., Artale, S. A., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605319 · Cited by 140 · see citing works
A randomized phase II trial of S-1-oxaliplatin versus capecitabine–oxaliplatin in advanced gastric cancer
Kim, G. M., Jeung, H., Rha, S. Y., Kim, H. S., Jung, I., Nam, B., Lee, K. H., & Chung, H. C. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.017 · Cited by 140 · see citing works
Structural Characterization and Anticancer Activity of Cell-Bound Exopolysaccharide from Lactobacillus helveticus MB2-1
Li, W., Xia, X., Tang, W., Ji, J., Rui, X., Chen, X., Jiang, M., Zhou, J., Zhang, Q., & Dong, M. (2015) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5b01086 · Cited by 140 · see citing works
Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis
Montagnani, F., Turrisi, G., Marinozzi, C., Aliberti, C., & Fiorentini, G. (2011) · Gastric Cancer · doi:10.1007/s10120-011-0007-7 · Cited by 139 · see citing works
Chemotherapy of advanced gastric cancer
Rivera, F., Vega-Villegas, M. E., & López-Brea, M. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.01.004 · Cited by 138 · see citing works
Ginger ingredients reduce viability of gastric cancer cells via distinct mechanisms
Ishiguro, K., Ando, T., Maeda, O., Ohmiya, N., Niwa, Y., Kadomatsu, K., & Goto, H. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.012 · Cited by 138 · see citing works
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
Lee, J.-L., Kang, Y.-K., Kang, H. J., Lee, K.-H., Zang, D. Y., Ryoo, B.-Y., Kim, J. G., Park, S. R., Kang, W. K., Shin, D. B., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604536 · Cited by 134 · see citing works
Thymoquinone inhibits growth and augments 5-fluorouracil-induced apoptosis in gastric cancer cells both in vitro and in vivo
Lei, X., Xiao-guang, L., Liu, M., Yang, Z., Ji, M., Guo, X., & Dong, W. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.12.063 · Cited by 132 · see citing works
Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial
Lorenzen, S., Hentrich, M., Haberl, C., Heinemann, V., Schuster, T., Seroneit, T., Röthling, N., Peschel, C., & Lordick, F. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm269 · Cited by 132 · see citing works
Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study
Moehler, M. H., Mueller, A., Trarbach, T., Lordick, F., Seufferlein, T. T. W., Kubicka, S., Geißler, M., Schwarz, S., Galle, P. R., & Kanzler, S. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq591 · Cited by 124 · see citing works
Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial
Okines, A. F. C., Ashley, S. E., Cunningham, D., Oates, J. R., Turner, A., Webb, J., Saffery, C., Chua, Y. J., & Chau, I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.2847 · Cited by 125 · see citing works
The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010
Cutsem, E. V., Dicato, M. A., Geva, R., Arber, N., Bang, Y., Benson, A. B., Cervantes, A. M. R., Díaz‐Rubio, E., Ducreux, M. P., Glynne‐Jones, R., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr284 · Cited by 123 · see citing works
Self-citation
Individualization of Drug Therapy: History, Present State, and Opportunities for the Future
Lesko, L. J., & Schmidt, S. O. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.113 · Cited by 121 · see citing works
Outcome Data of Patients with Peritoneal Carcinomatosis from Gastric Origin Treated by a Strategy of Bidirectional Chemotherapy Prior to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in a Single Specialized Center in Japan
Canbay, E., Mizumoto, A., Ichinose, M., Ishibashi, H., Sako, S., Hirano, M., Takao, N., & Yonemura, Y. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3443-2 · Cited by 120 · see citing works
Gastric cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Jackson, C., Cunningham, D., & Oliveira, J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp122 · Cited by 119 · see citing works
Surgical treatment for peritoneal carcinomatosis from gastric cancer
Yonemura, Y., Endou, Y., Sasaki, T., Hirano, M., Mizumoto, A., Matsuda, T., Takao, N., Ichinose, M., Miura, M., & Li, Y. (2010) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2010.09.006 · Cited by 118 · see citing works
Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum
Jh, Y., Lee, J., Lee, J., Jo, P., Park, J. O., Yim, D.-S., Park, Y. S., Lim, H. Y., & Kang, W. K. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.100 · Cited by 116 · see citing works
MicroRNAs as potential biomarkers for gastric cancer
Liu, H. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i34.12007 · Cited by 114 · see citing works
Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
Satoh, T., Lee, K., Rha, S., Sasaki, Y., Park, S., Komatsu, Y., Yasui, H., Kim, T.-Y., Yamaguchi, K., Fuse, N., et al. (2014) · Gastric Cancer · doi:10.1007/s10120-014-0420-9 · Cited by 123 · see citing works
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study
Rao, S., Starling, N., Cunningham, D., Sumpter, K., Gilligan, D., Ruhstaller, T., Valladares‐Ayerbes, M., Wilke, H., Archer, C., Kurek, R., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq247 · Cited by 113 · see citing works
Exosome-Delivered c-Met siRNA Could Reverse Chemoresistance to Cisplatin in Gastric Cancer
Zhang, Q., Zhang, H., Ning, T., Liu, D., Deng, T., Liu, R., Bai, M., Zhu, K., Li, J., Qian, F., et al. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s231214 · Cited by 112 · see citing works
Prognostic Significance of Neutrophil Lymphocyte Ratio in Patients with Gastric Cancer: A Meta-Analysis
Zhang, X., Zhang, W., & Feng, L.-J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111906 · Cited by 111 · see citing works
A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma
Xiao, X., Liu, Y. W., Zhang, L., Qiu, F., Feng, Y. Y., Zhan, Z. Y., Feng, M., Yan, J., Zhao, J. G., & Xiong, J. P. (2012) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328350dd0d · Cited by 111 · see citing works
miR-874 functions as a tumor suppressor by inhibiting angiogenesis through STAT3/VEGF-A pathway in gastric cancer
Zhang, X., Tang, J., Zhi, X., Xie, K.-L., Wang, W., Li, Z., Zhu, Y., Yang, L., Xu, H., & Xu, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.2748 · Cited by 110 · see citing works
Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial
Tsuburaya, A., Yoshida, K., Kobayashi, M., Yoshino, S., Takahashi, M., Takiguchi, N., Tanabe, K., Takahashi, N., Imamura, H., Tatsumoto, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70025-7 · Cited by 109 · see citing works
S3-Leitlinie Magenkarzinom – Diagnostik und Therapie der Adenokarzinome des Magens und des ösophagogastralen Übergangs – Langversion 2.0 – August 2019. AWMF-Registernummer: 032/009OL
Moehler, M. H., Al-Batran, S.-E., Andus, T., Arends, J., Arnold, D., Baretton, G. B., Bornschein, J., Budach, W., Daum, S., Dietrich, C. G., et al. (2019) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1018-2516 · Cited by 104 · see citing works
Esophageal cancer chemotherapy: recent advances.
Ilson, D. H. (2008) · PubMed Central · Cited by 104 · see citing works
RETRACTED: Curcuminoid B63 induces ROS-mediated paraptosis-like cell death by targeting TrxR1 in gastric cells
Chen, X., Chen, X., Zhang, X., Wang, L., Cao, P., Rajamanickam, V., Wu, C., Zhou, H., Cai, Y., Liang, G., et al. (2018) · Redox Biology · doi:10.1016/j.redox.2018.11.019 · Cited by 102 · see citing works
Retracted
Intratumoral Heterogeneity Determines Discordant Results of Diagnostic Tests for Human Epidermal Growth Factor Receptor (HER) 2 in Gastric Cancer Specimens
Yang, J., Luo, H., Li, Y., Li, J., Cai, Z., Su, X., Dai, D., Du, W., Chen, T., & Chen, M. (2011) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-011-9286-1 · Cited by 101 · see citing works
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
Catalano, V., Graziano, F., Santini, D., D'Emidio, S., Baldelli, A. M., Rossi, D., Vincenzi, B., Giordani, P., Alessandroni, P., Testa, E., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604732 · Cited by 101 · see citing works
Palliative radiotherapy for bleeding from advanced gastric cancer: is a schedule of 30 Gy in 10 fractions adequate?
Asakura, H., Hashimoto, T., Harada, H., Mizumoto, M., Furutani, K., Hasuike, N., Matsuoka, M., Ono, H., Boku, N., & Nishimura, T. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0866-z · Cited by 101 · see citing works
An Analytics Approach to Designing Combination Chemotherapy Regimens for Cancer
Bertsimas, D., O'Hair, A., Relyea, S. L., & Silberholz, J. (2016) · Management Science · doi:10.1287/mnsc.2015.2363 · Cited by 100 · see citing works

Combination chemotherapies in advanced gastric cancer: An updated systematic review and meta-analysis
Wagner, D., Grothe, W., Haerting, J., Kleber, G., Grothey, A. F., & Fleig, W. E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.4555 · Cited by 6 · see citing works
Self-citation
Chemotherapy in advanced gastric cancer: what is the evidence?
Wagner, A., Grothe, W. W., Grothey, A., Haerting, J., & Kleber, G. (2005) · Zeitschrift für Gastroenterologie · doi:10.1055/s-2005-920138
Self-citation
Chemotherapy for advanced gastric cancer
Wagner, D., Unverzagt, S., Grothe, W., Kleber, G., Grothey, A., Haerting, J., & Fleig, W. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub3 · Cited by 470 · see citing works
Self-citation
Novel Chemotherapy Combinations in Advanced Gastric Cancer: an Updated Meta-Analysis
Wagner, D., Unerzagt, S., Grothe, W., Kleber, G., Grothey, A. A., Haerting, J., & Fleig, W. E. (2010) · IRIS · Cited by 1 · see citing works
Self-citation
Irinotecan in the treatment of gastric cancer
Bugat, R. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg727 · Cited by 29 · see citing works

Authors: Wagner, A. D., Grothe, W., Haerting, J., Kleber, G., Grothey, A., & Fleig, W. E.
Affiliations: From the First Department of Medicine, Coordinating Centre for Clinical Trials, Department of Medicine IV, and Institute of Medical Epidemiology, Biostatistics and Informatics, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany; and Mayo Clinic College of Medicine, Rochester, MN
Mayo Clinic (US)
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2006-06-20
Volume: 24
Issue: 18
Pages: 2903-2909
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2005.05.0245
OpenAlex: W2145390243
Cited by: 1,171
References: 51
Citations by year: 2026: 7 · 2025: 15 · 2024: 26 · 2023: 28 · 2022: 34 · 2021: 64 · 2020: 55 · 2019: 54 · 2018: 69 · 2017: 89 · 2016: 72 · 2015: 84 · 2014: 105 · 2013: 92 · 2012: 77
FWCI: 9.54
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: American Society of Clinical Oncology
Bundesministerium für Bildung und Forschung (01GH0105)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Gastric Cancer Management and Outcomes
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
Keywords: advanced gastric cancer, first-line chemotherapy, 5-fluorouracil, cisplatin, anthracyclines, irinotecan, combination chemotherapy, overall survival, best supportive care, epirubicin, chemotherapy toxicity
MeSH terms: Antineoplastic Combined Chemotherapy Protocols, Humans, Stomach Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks